🌟 Yesterday, on February 4th, we marked World Cancer Day. A day to reflect on the global impact of cancer, a disease claiming the lives of approximately 8 million people annually. Many of these losses can be averted through prevention, early detection, and effective treatment.
At INESC TEC, we are passionately dedicated to establishing robust research initiatives leveraging artificial intelligence to enhance the diagnosis and management of cancer. I'm thrilled to share that we are embarking on a new European project, the first one coordinated by us under the Horizon Europe framework in the health sector. This initiative aims to develop AI methods specifically tailored for respiratory diseases, with lung cancer being a use case.
Our commitment at INESC TEC extends to tackling solutions for various cancers, including breast, lung, colorectal, prostate, pancreas, esophagus/stomach, cervical, bladder, and neuroblastoma. Our endeavors predominantly involve cutting-edge applications in image analysis. Let's work towards a future where preventable losses are minimized, and more lives are saved. 🌐💙
#CancerResearch #ArtificialIntelligence #HorizonEurope #HealthTech #INESCTEC #WorldCancerDay
🌐 For the first time, #INESCTEC leads a large-scale European project (€6.9M) entirely focused on lung diseases.💡
It's called AI4Lungs —a €6.9M initiative solely dedicated to revolutionizing how we approach lung diseases.
Imagine a future where AI streamlines diagnosis and treatment processes for respiratory conditions, from pneumonia to COVID-19, to cancer. AI4Lungs leverages diverse clinical data sources, making it a game-changer for physicians and facilitating the clinical processing of patients with any symptom of respiratory disease, reducing costs, and optimising the allocation of resources. 🤖💼
Here's what you need to know 👇
https://lnkd.in/d5BHpMBc
Hélder P. Oliveira | Duarte Dias | i3S - Instituto de Investigação e Inovação em Saúde | #CHVNGE #AI4Lungs #HealthcareInnovation #MedicalAI #RespiratoryHealth
Asst Professor of Bioinformatics & ML | Co-Founder at MedAiHealth | Entrepreneur | Inclusive AI | Health Inequality | Human Centric AI
3moThis is very interesting. I remember their results published in ESMO 2020. There was a stark difference in the performances between stage I-II and stage III-IV cancers. The number of samples in the test sets across different cancer types were also quite low.